Targeting obesity for therapeutic intervention in heart failure patients.
Ryosuke SatoStephan von HaehlingPublished in: Expert review of cardiovascular therapy (2024)
The STEP HFpEF (Semaglutide Treatment Effect in People with obesity and HFpEF) and SELECT (Semaglutide Effects on Cardiovascular Outcomes in People with Overweight or Obesity) trials recently demonstrated that the glucagon-like peptide 1 analogue, semaglutide, improves various aspects of clinical outcomes in obese HFpEF patients and significantly reduces cardiovascular and heart failure events in non-diabetic obese patients, along with a substantial weight loss. Future clinical trials with other incretin mimetics with more potent weight loss and sub-analyses of the SELECT trial may further emphasize the importance of the obesity phenotype-based approach in the treatment of HFpEF.
Keyphrases
- weight loss
- bariatric surgery
- obese patients
- roux en y gastric bypass
- gastric bypass
- clinical trial
- heart failure
- weight gain
- metabolic syndrome
- type diabetes
- ejection fraction
- insulin resistance
- end stage renal disease
- glycemic control
- randomized controlled trial
- newly diagnosed
- study protocol
- high fat diet induced
- chronic kidney disease
- body mass index
- atrial fibrillation
- left ventricular
- cancer therapy
- combination therapy
- current status